8-K current report · filed Aug 26, 2026

Revolution Medicines Inc (RVMD) 8-K Current Report: August 26, 2026

Item 8.01RVMD overview

Short answer

Revolution Medicines Inc (RVMD) filed an 8-K current report with the SEC on August 26, 2026 reporting Item 8.01 (Other Events). FDA approval of RASONQUE, daraxonrasib, for previously treated metastatic pancreatic adenocarcinoma.

Revolution Medicines Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • FDA approval of RASONQUE, daraxonrasib, for previously treated metastatic pancreatic adenocarcinoma
  • Approval supported by RASolute 302, a randomized Phase 3 trial versus investigator-selected chemotherapy
  • U.S. commercial launch underway with once-daily oral tablets available to eligible patients
  • Wholesale acquisition cost: $39,800 per 30-day supply, establishing a significant commercial revenue opportunity

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Revolution Medicines Inc 8-K filings

Get the next RVMD 8-K as it lands

Follow RVMD for push alerts, or ask the research agent what this filing means.